

# Cleidocranial dysplasia. A molecular and clinical review

Andrea Avendaño<sup>1</sup>, Francisco Cammarata-Scalisi<sup>1</sup>, Mochamad Fahlevi Rizal<sup>2</sup>, Sarworini Bagio Budiardjo<sup>2</sup>, Margaretha Suharsini<sup>2</sup>, Eva Fauziah<sup>2</sup>, Nicola Maria Grande<sup>3</sup>, Leonzio Fortunato<sup>3</sup>, Gianluca Plotino<sup>4</sup>, İzzet Yavuz<sup>5</sup>, Michele Callea<sup>6</sup>

<sup>1</sup> University Hospital of Los Andes (IAHULA), Unit of Medical Genetics, Mérida- Venezuela

<sup>2</sup> Universitas Indonesia, Faculty of Dentistry, Department of Pediatric Dentistry, Jakarta, Indonesia

<sup>3</sup> University of Magna Grecia (UMG), Department of Scienze Mediche e Chirurgiche, Catanzaro, Italy

<sup>4</sup> Private Practice, Rome, Italy

<sup>5</sup> Dicle University, Department of Pediatric Dentistry, Diyarbakir, Turkey

<sup>6</sup> Unit of Dentistry, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

## Correspondence:

Dr. Andrea Avendaño

University Hospital of Los Andes (IAHULA), Unit of Medical Genetics, Mérida- Venezuela

E-mail:

andrea.avendano1007@gmail.com

Received: 19 January 2018

Accepted: 12 February 2018

## Abstract

Cleidocranial dysplasia (CCD) is a rare autosomal dominant disorder characterized by skeletal and dental abnormalities primarily, short stature, aplasia or hypoplasia of clavicles, open fontanelles and supernumerary teeth. Heterozygous mutations of the runt-related transcription factor 2 (*RUNX2*) gene have been found in approximately 60-70% of cases, leaving a large number of cases with no defined genetic cause which led us to delve into molecular mechanisms underlying CCD and thus to detect potential target genes to be explored in these patients. In this review, we also highlight very broadly the phenotypic characteristics of previously reported patients with CCD.

**Keywords:** Cleidocranial dysplasia, *RUNX2* gene, supernumerary teeth

**How to cite this article:** Avendaño A, Cammarata-Scalisi F, Rizal MF, Budiardjo SB, Suharsini M, Fauziah E, Grande NM, Fortunato L, Plotino G, Yavuz I, Callea M. Cleidocranial dysplasia. A molecular and clinical review. *Int Dent Res* 2018;8(1):35-38.

### Access Online



DOI:

10.5577/intdentres.2018.vol8.no1.6

## Introduction

Cleidocranial dysplasia (CCD, OMIM #119600) is an autosomal dominant dysplasia of skeletal and dental tissues, characterized by aplasia or hypoplasia of clavicles, multiple Wormian bones, failure of midline

ossification, delayed tooth eruption, supernumerary teeth and other skeletal abnormalities. CCD was accurately described at the end of the 18th century. Nevertheless, a hundred years later it was coined as “dysostosis cleidocranial hereditary” (1, 2). Hesse was first to describe dental defects in patients with CCD

(3). Since then a lot of information has been published, in particular a comprehensive study was carried out in order to describe skeletal abnormalities, these observations lead researchers to propose the term cleidocranial dysplasia (1, 4). CCD is a congenital disorder with an incidence of 1 in 1.000.000 newborns and more than 1.000 cases have been reported so far. Mutations in runt-related transcription factor 2 gene (*RUNX2*, OMIM #600211) have been associated with the molecular basis of this disorder. *RUNX2* codify for a core-binding transcription factor protein (CBFA1 or *RUNX2*), which plays an important role in the differentiation of osteoblasts, chondrocyte maturation and regulation of bone metabolism (5, 6). This comprehensive review discusses insights into molecular pathways of the molecular mechanism causing CCD and the multiple phenotypes so far encountered and reported in literature underlining the importance of the dentist in the management of supernumerary teeth.

### RUNX2 role in Osteogenesis

*RUNX2* has an important role in both osteogenesis pathways and belongs to *RUNX* family, a transcription factor family, which forms heterodimers with *CBFB* and recognizes a consensus sequence in DNA (5). *RUNX2* is expressed only in chondrocyte and osteoblast progenitors and mature osteoblasts (7). *RUNX2*, *SP7*, and canonical Wnt signaling have been associated with the commitment of mesenchymal stem cells to the osteoblastic lineage during osteoblast differentiation. Likewise, *RUNX2* complex has been involved in the terminal chondrocytes differentiation, an essential step for ossification (6). Moreover, *RUNX2* upregulates *OSTERIX* gene and other such as *SPARC*, *SPP1*, and *COL1A1*, all of these are important for bone maturation. In the same way, classic Wnt pathway, bone morphogenetic protein (BMP) and fibroblast growth factors (FGFs) regulate *RUNX2* expression (8–10). *RUNX2* has also demonstrated controlling expression of mesenchymal tissue through differentiation of dental epithelium, which could lead to dental anomalies found in CCD patients (11). Recently, a group of miRNAs, have been demonstrated to regulate osteogenesis by targeting *RUNX2* (12–14).

### Genetics of CCD

Heterozygous mutations in *RUNX2* gene are widely recognized as the main cause of CCD. *RUNX2*, also called *CBFA1*, *AML3* and *PEBP2aA*, is composed of 8 exons and maps on the short arm of chromosome 6 (6p21) (15, 16). Mutations in *RUNX2* have a complete penetrance and some of these could present variable expressivity, the phenotype can range from single

dental anomalies to a severe phenotype with all clinical features including osteoporosis (17). So far, more than 100 mutations have been reported, including, 80 point mutations, 11 affecting splicing, 47 small deletions, 28 small insertions, 2 small indels, 22 and 8 gross deletions and insertions, respectively, 4 chromosomal rearrangements and 4 mutations altering the number of polyglutamine repeated sequence located in Q/A domain (Human Gene Mutation Database, (<http://www.hgmd.cf.ac.uk>). However, mutations in *RUNX2* have only been reported in 60-70% of patients with CCD and microdeletions matching with contiguous gene deletions in 13-28% of cases, which could suggest an important role of other components not yet described, involved in the signaling pathway of *RUNX2* gene (18, 19).

### Clinical characteristics of CCD

CCD is a skeletal dysplasia, which is known to be associated with several bone defects such as, Wormian bones, hypoplasia or agenesis of clavicle, macrocephaly, frontal bossing, mid face hypoplasia, mandibular prognathism, delayed closure of the fontanels, the short stature, dental anomalies in the number and shape and wide pubic symphysis (7, 17, 18). Other common characteristics were hypoplasia of maxilla and hypertelorism, short middle phalanx of the fifth finger and brachycephalic head (20). Recently, two previously reported patients and one of our patients showing a clear CCD phenotype shared a remarkable clinical finding such as some blood malignancies, leading us to propose a correlation between some mutations in *CBFA1* domain of *RUNX2* gene and acute myeloid leukemia and acute lymphoid leukemia (21–24).

### Oral manifestations of CCD

The most important dental features include altered eruption patterns: usually in these patients primary teeth are retained and an eruption of permanent teeth is delayed, the presence of supernumerary teeth, misshapen teeth and tooth agenesis (21). Severe dental anomalies have been associated with mutations located in runt domain (20). However, we have reported the p.R131C mutation located in runt domain, in which patients carrying this mutation did not present supernumerary teeth (18, 25). Other cases with no supernumerary teeth have been reported, but the mutation is not located in runt domain, considering that mutations in an extra-runt region are usually associated with mild phenotypes, the clinical finding is not surprising (20). Moreover, intrafamilial variations have been frequently reported in dental features, mainly in the number of

supernumerary teeth, ranging from 1 to 20 teeth, indeed environmental and epigenetic factors have been proposed as the mechanism mediating these phenotypes in CCD patients (20, 26). Also, patients with CCD displayed significant changes in dentin and inadequate mineralization, showing a reduction in calcium and phosphate and carbon and oxygen composition was increased (27).

## Orthodontic treatment in CCD

Radiological and clinical approaches are the most important and consistent signs and symptoms to confirm diagnosis, therefore, patients with CCD should be carefully evaluated by a dental multi specialist team due to the complexity of the treatment foreseen. Dental anomalies are one of the most important stigmata of these patients; unfortunately, guideline for management of CCD patients is scarce and depends on the severity of dental anomalies, however, basically, extractions of supernumerary (and their possible transplantation) teeth and to use removable or fixed orthodontic devices in order to align teeth after the extraction/autologous transplantation, and sometimes to guide the eruption and the subsequent alignment of teeth in order to improve life quality of patients (28–31).

## Conclusions

CCD is a disorder with intra and interfamilial clinical variability; several organs are affected in these patients, thus, a multidisciplinary specialist team constituted by radiologist, neurologist, geneticist, pediatricians, surgeon and pediatric dentist should evaluate patients in order to provide the best care. Oral manifestations could become a problem to develop a normal life, so it is important to start orthodontic treatments at an early age.

**Peer-review:** Externally peer-reviewed.

**Author Contributions:** Conception - A.A, M.C.; Design - I.Y., F.C.S., N.M.G., L.F., G.P.; Supervision - I.Y., M.F.R., S.B.B., N.M.G., L.F., G.P.; Materials - M.C., S.B.B.; Data Collection and/or Processing - A.A., F.C.S., M.S., E.F.; Analysis and/or Interpretation - M.C., F.C.S., M.F.R., M.S., E.F.; Literature Review - S.B.B., M.S., E.F., N.M.G., L.F., G.P.; Writer - A.A., M.C.; Critical Review - M.C., M.F.R., S.B.B., N.M.G., L.F., G.P.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

## References

1. Roberts T, Stephen L, Beighton P. Cleidocranial dysplasia: A review of the dental, historical, and practical implications with an overview of the South African experience. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2013;115:46-55. [\[Crossref\]](#)
2. Mundlos S. Cleidocranial dysplasia: clinical and molecular genetics. *J Med Genet* 1999;36:177-82.
3. Patil P, Barpande S, Bhavthankar J, Humbe J. Cleidocranial dysplasia: A clinico-radiographic spectrum with differential diagnosis. *J Orthop Case Reports* 2015;5:21-4.
4. Jensen B. Somatic development in cleidocranial dysplasia. *Am J Med Genet* 1990;35:69-74. [\[Crossref\]](#)
5. Komori T. Signaling networks in RUNX2-dependent bone development. *J Cell Biochem* 2011;112:750-5. [\[Crossref\]](#)
6. Komori T. Regulation of bone development and extracellular matrix protein genes by RUNX2. *Cell Tissue Res* 2010;339:189-95. [\[Crossref\]](#)
7. Bharti K, Goswami M. Cleidocranial dysplasia: A report of two cases with brief review. *Intractable Rare Dis Res* 2016;5(2):117-20. [\[Crossref\]](#)
8. Åberg T, Wang X, Kim J, Yamashiro T, Bei M, Rice R, et al. Runx2 mediates FGF signaling from epithelium to mesenchyme during tooth morphogenesis. *Dev Biol* 2004;270:76-93. [\[Crossref\]](#)
9. Zhang Y, Yasui N, Ito K, Huang G, Fujii M, Hanai J, et al. A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. *Proc Natl Acad Sci* 2000;97:10549-54. [\[Crossref\]](#)
10. Valenti MT, Dalle Carbonare L, Mottes M. Osteogenic differentiation in healthy and pathological conditions. *Int J Mol Sci* 2016;18:e41-9. [\[Crossref\]](#)
11. Jaruga A, Hordyjewska E, Kandzierski G, Przemk T. Cleidocranial dysplasia and RUNX2-clinical phenotype genotype correlation. *Clin Genet* 2016;90:393-402. [\[Crossref\]](#)
12. Liu H, Sun Q, Wan C, Li L, Zhang L, Chen Z. MicroRNA-338-3p regulates osteogenic differentiation of mouse bone marrow stromal stem cells by targeting Runx2 and Fgfr2. *J Cell Physiol* 2014;229:1494-502. [\[Crossref\]](#)
13. Du F, Wu H, Zhou Z, Liu Y. MicroRNA-375 inhibits osteogenic differentiation by targeting runt-related transcription factor 2. *Exp Ther Med* 2015;10:207-12. [\[Crossref\]](#)
14. Sera SR, Zur Nieden NI. microRNA regulation of skeletal development. *Curr Osteoporos Rep* 2017;15(4):353-66. [\[Crossref\]](#)
15. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. *Genomics* 1994;23:425-32. [\[Crossref\]](#)
16. Mundlos S, Olsen BR. Heritable diseases of the skeleton. Part II: Molecular insights into skeletal development-matrix components and their homeostasis. *FASEB J* 1997;11:227-33. [\[Crossref\]](#)
17. Callea M, Fattori F, Bertini B, Yavuz I, Bellacchio E, Avendaño A, et al. Estudio clínico y molecular en una familia con displasia cleidocraneal. *Arch Argent Pediatr* 2017;115:e39-e42.
18. Callea M. A case of cleidocranial dysplasia with peculiar dental features: pathogenetic role of the RUNX2 mutation and long term follow-up. *Oral Heal Dent Manag.* 2014;13:548-51.
19. Lee MTM, Tsai A, Chou C, Sun F, Huang L, Yen P, et al. Intragenic microdeletion of RUNX2 is a novel mechanism for cleidocranial dysplasia. *Genomic Med* 2008;2:45-9. [\[Crossref\]](#)
20. Bufalino A, Paranaíba L, Gouvêa A, Gueiros A, Martelli-Júnior H, Junior J, et al. Cleidocranial dysplasia: Oral features and genetic analysis of 11 patients. *Oral Dis* 2012;18:184-90. [\[Crossref\]](#)
21. Gardham A, Forsythe E, Goulden N. One in 10 million: a case of cleidocranial dysplasia and acute lymphoblastic leukemia-more than just a coincidence?. *Clin Dysmorphol* 2012;21:170-171. [\[Crossref\]](#)
22. Schnerch D, Lausch E, Becker H, Felthaus J, Pfeifer D, Mundlos S, et al. Upregulation of Runx2 in acute myeloid leukemia in a patient with an inherent Runx2 haploinsufficiency and cleidocranial dysplasia. *Leuk Lymphoma* 2013;55:1930-2. [\[Crossref\]](#)

23. Callea M, Fattori F, Bertini ES, Cammarata-Scalisi F, Callea F, Bellacchio E. Blood malignancies presenting with mutations at equivalent residues in RUNX1-2 suggest a common leukemogenic pathway. *Leuk Lymphoma* 2017;58:2002-4. [\[Crossref\]](#)
24. Callea M, Bellacchio E, Fattori F, Bertini E, Callea F, Cammarata-Scalisi F. Acute myeloid leukemia in a 3 years old child with cleidocranial dysplasia. *Leuk Lymphoma* 2016;57:2189-91. [\[Crossref\]](#)
25. Callea M, Fattori F, Yavuz I, Bertini E. A new phenotypic variant in cleidocranial dysplasia (CCD) associated with mutation c.391C>T of the RUNX2 gene. *BMJ Case Rep* 2012;2012. [\[Crossref\]](#)
26. Suda N, Hamada T, Hattori M, Moriyama K, Torii C, Kosaki K. Diversity of supernumerary tooth formation in siblings with cleidocranial dysplasia having identical mutation in RUNX2: Possible involvement of non-genetic or epigenetic regulation. *Orthod Craniofacial Res* 2007;10:222-5. [\[Crossref\]](#)
27. Xuan D, Sun X, Yan Y, Xie B, Xu P, Zhang J. Effect of cleidocranial dysplasia-related novel mutation of RUNX2 on characteristics of dental pulp cells and tooth development. *J Cell Biochem* 2010;111:1473-81. [\[Crossref\]](#)
28. Li Z-J, Wang J-Y, Gao M-F, Wu D-L, Chang X. Orthodontic treatment of a patient with cleidocranial dysplasia: A case report. *Exp Ther Med* 2016;12:690-4. [\[Crossref\]](#)
29. Farronato G, Maspero C, Farronato D, Gioventù S. Orthodontic treatment in a patient with cleidocranial dysostosis. *Angle Orthod* 2009;79:178-85. [\[Crossref\]](#)
30. Atil F, Culhaoglu A, Kocyigit ID, Adisen Z, Misirlioglu M, Yilmaz B. Oral rehabilitation with implant-supported fixed dental prostheses of a patient with cleidocranial dysplasia. *J Prosthet Dent* 2018;119(1):12-16. [\[Crossref\]](#)
31. Garg RK, Agrawal P. Clinical spectrum of cleidocranial dysplasia: a case report. *Cases J* 2008;1:377. [\[Crossref\]](#)